Catalent Plans to Showcase Technology and Expansions at CPhI 2014
CPhI Worldwide 2014 brings new technology and expansions from Catalent.
Catalent Pharma Solutions will be located at booth 2C9 at CPhI Worldwide 2014, in Paris, France. At the booth, Catalent will be speaking about their facilities located in China and Japan, as well as their integrated platform facilities that meet needs in biomanufacturing, hot-melt extrusion, aseptic technologies, and softgels in Germany and the US.
As part of the Pre-Connect Conference on Monday, Oct. 6, 2014, Catalent presented sessions on drug-delivery systems, biopharmaceuticals, biosimilars, and new trends in oncology, featuring speakers from Catalent.
Continuing during the exhibition, Catalent executives will be speaking as part of the Speaker’s Corner program on October 7 and 8. Speakers will cover regulatory excellence, audits, and supply-chain practices and processes. Insight briefings will be held during the show, in which Catalent will participate on October 8 and 9 with experts speaking about drug-delivery techniques and skills and trends in the pharmaceutical industry.
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
